Navigation Links
CVBT Interim Board of Directors Remains In Place

LAS VEGAS, June 21, 2013 /PRNewswire/ -- CardioVascular BioTherapeutics, Inc. (CVBT) announced today that the Delaware Court of Chancery ruled that Mickael A. Flaa, Grant Gordon, Calvin A. Wallen III, Jon Ross, and Robert Schleizer will remain in place as the CVBT Board of Directors pending resolution of the lawsuit filed on June 9, 2013, by Mickael A. Flaa in that Court.  The Delaware lawsuit seeks, among other things, to confirm the validity of the action by written consent of stockholders on June 7, 2013, to remove Daniel C. Montano, John (Jack) Jacobs, Ernest C. Montano, Viktoriya T. Montano, Ernest Montano III, and Joong Ki Baik as directors of CVBT.  Pending resolution of the Delaware lawsuit, or further order of the Delaware Court of Chancery, the power of CVBT's interim Board of Directors to take certain [extraordinary] actions on behalf of CVBT will be limited by a status quo order, which has not yet been entered.

About CardioVascular BioTherapeutics
CVBT is a biopharmaceutical company developing drug candidates with FGF-1 as its active pharmaceutical ingredient (API) for diseases characterized by inadequate blood flow to tissue or organs. The company is the sponsor of a Phase II trial to treat severe coronary heart disease (CVBT-141H), and has received FDA authorization for a Phase I trial to treat peripheral arterial disease (CVBT-141C). A Late-Stage trial to treat chronic diabetic foot ulcers (CVBT-141B) is planned pending FDA approval.

Forward Looking Statements
This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.

Media Contacts:
Allison Caplan
CardioVascular BioTherapeutics, Inc.
(702) 839-7200

CVBT Mailing List
To be added to the CVBT Mailing List, please send your contact information to


SOURCE CardioVascular BioTherapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. GW Pharmaceuticals to Report Interim 2013 Results and Host Conference Call on 3 June, 2013
2. New Interim Analysis From Observational Study Suggests That Delivery Of Insulin Via Valeritas V-Go Shows Promise In Improving Glycemic Control For Patients With Type 2 Diabetes
3. Immunomic Therapeutics Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy
4. Relievant Medsystems Achieves Completion of Interim Safety Data Analysis of Intracept in SMART Pivotal Study and Expands Senior Leadership Team
5. Inovio Collaborator ChronTech Reports Interim Phase II Clinical Study Results from ChronVac-C Vaccine for Hepatitis C Infection
6. Convergence Pharmaceuticals Announces Successful Interim Data from Ground-Breaking Phase II Trigeminal Neuralgia Study
7. OncoSec Medical Updates Analysis of Interim Data for Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
8. Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
9. Avanir Pharmaceuticals Announces Positive Interim Data From Pharmacokinetic Study With Next Generation Compound AVP-786
10. Vermillion Appoints Bruce A. Huebner as Interim Chief Executive Officer
11. Golden Meditech Announces 2012 / 2013 Interim Results
Post Your Comments:
(Date:11/30/2015)... Fla. , Nov. 30, 2015   The ... (the Institute) announced today that it has finalized a ... start-up company with technology developed at Florida State University. ... research, and bridges early funding gaps for companies spinning ... research institutions. --> ...
(Date:11/30/2015)... India , November 30, 2015 ... --> adds ... trends for 2010 - 2015 with ... for a range of deal types, ... and strategic alliances. ...
(Date:11/30/2015)... PUNE, India , November 30, 2015 ... new market research report "Dental Lasers Market by Product (Soft ... Treatment, Periodontitis), End User (Hospitals, Clinics), and Geography - Global ... USD 224.7 Million by 2020, at a CAGR of 5.2% ... , Browse 140 market data Tables and 62 Figures spread ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... The successful filing of ... company. Because it is so important to this key industry segment, Regis Technologies has ... IND Filing” on December 4th at 11am EST. , Federal law does not allow ...
(Date:11/30/2015)... ... November 30, 2015 , ... Healthjump, Inc. announced that it ... IT consulting, development and support company. The purchase will expand the capability to ... to extend the services currently provided by Healthjump. , Through this ...
(Date:11/30/2015)... Puerto Rico (PRWEB) , ... November 30, 2015 , ... ... active part of the San Juan Beauty Show held on November 8th and 9th ... was attended by media personalities, hair artists, renowned beauticians and top of the line ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... healthcare professionals worldwide today released the results of a survey of educational needs ... and Africa found a growing global demand for high quality online and face-to-face ...
(Date:11/30/2015)... MN (PRWEB) , ... November 30, 2015 , ... ... of a new product dealer. Joining more than 30 HealthPostures’ dealers located throughout ... foot space and increase the number of corporate, industrial, manufacturing and government workers ...
Breaking Medicine News(10 mins):